Aytu BioPharma, Inc. (AYTU)
NASDAQ$1.2049
Market Cap
$7.43M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
371 of 924
Rank in Industry
19 of 56
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
AYTU Insider Trading Activity
AYTU Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $19,500 | 1 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Disbrow Joshua R. | Chief Executive Officer | 1 | $19,500 | 0 | $0 | $19,500 |
About Aytu BioPharma, Inc.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine …
Insider Activity of Aytu BioPharma, Inc.
Over the last 12 months, insiders at Aytu BioPharma, Inc. have bought $19,500 and sold $0 worth of Aytu BioPharma, Inc. stock.
On average, over the past 5 years, insiders at Aytu BioPharma, Inc. have bought $2.05M and sold $9.44M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Disbrow Joshua R. (Chief Executive Officer) — $19,500.
The last purchase of 15,000 shares for transaction amount of $19,500 was made by Disbrow Joshua R. (Chief Executive Officer) on 2025‑02‑28.
List of Insider Buy and Sell Transactions, Aytu BioPharma, Inc.
| 2025-02-28 | Disbrow Joshua R. | Chief Executive Officer | 15,000 0.245% | $1.30 | $19,500 | -2.71% | ||
| 2023-06-16 | PYSZCZYMUKA GREG | Chief Commerical Officer | 12,000 0.3307% | $1.87 | $22,428 | +53.30% | ||
| 2023-06-14 | Disbrow Joshua R. | Chief Executive Officer | 14,000 0.3999% | $1.86 | $26,079 | +59.14% | ||
| 2022-12-19 | Disbrow Joshua R. | Chief Executive Officer | 112,371 0.1842% | $0.22 | $25,048 | -47.73% | ||
| 2022-12-19 | PYSZCZYMUKA GREG | Chief Commercial Officer | 100,000 0.18% | $0.24 | $24,480 | -47.73% | ||
| 2022-11-18 | Disbrow Joshua R. | Chief Executive Officer | 222,000 0.3705% | $0.24 | $52,614 | -50.00% | ||
| 2022-11-18 | Oki Mark K | Chief Financial Officer | 90,000 0.1458% | $0.23 | $20,700 | -50.00% | ||
| 2020-12-11 | ARMISTICE CAPITAL, LLC | director | 1.33M 9.5911% | $6.00 | $8M | -17.04% | ||
| 2020-04-27 | Sale | ARMISTICE CAPITAL, LLC | director | 5.11M 4.0608% | $1.82 | $9.3M | -49.75% | |
| 2020-04-15 | Sale | Cerecor Inc. | 10 percent owner | 92,777 0.082% | $1.55 | $144,092 | -33.23% | |
| 2020-03-10 | Sale | ARMISTICE CAPITAL, LLC | director | 22.03M 43.1464% | $1.42 | $31.2M | -41.46% | |
| 2019-12-20 | ARMISTICE CAPITAL, LLC | 26,000 0.1525% | $0.88 | $22,880 | +39.53% | |||
| 2019-12-19 | ARMISTICE CAPITAL, LLC | 52,788 0.3082% | $0.85 | $44,870 | +44.58% | |||
| 2019-12-19 | Disbrow Joshua R. | 55,000 0.3354% | $0.89 | $48,824 | +44.58% | |||
| 2018-12-21 | Sale | Green David A | Chief Financial Officer | 3,330 0.053% | $0.81 | $2,711 | +74.68% | |
| 2018-03-06 | Disbrow Joshua R. | Chief Executive Officer | 226,105 2.044% | $0.45 | $101,747 | -49.76% | ||
| 2018-03-06 | Disbrow Jarrett | Chief Operating Officer | 226,105 2.044% | $0.45 | $101,747 | -49.76% | ||
| 2018-03-06 | Green David A | Chief Financial Officer | 66,600 0.6021% | $0.45 | $29,970 | -49.76% | ||
| 2016-11-02 | Disbrow Joshua R. | Chief Executive Officer | 333,332 4.4318% | $1.68 | $559,998 | -70.09% | ||
| 2016-11-02 | Disbrow Jarrett | Chief Operating Officer | 333,332 4.4318% | $1.68 | $559,998 | -70.09% |
Total: 27
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Disbrow Joshua R. | Chief Executive Officer | 86591 1.4035% | $104,333.50 | 9 | 0 | <0.0001% |
| DOCKERY CARL | director | 5047591 81.8106% | $6.08M | 1 | 0 | |
| ARMISTICE CAPITAL, LLC | director | 1333334 21.6105% | $1.61M | 3 | 2 | <0.0001% |
| Disbrow Jarrett | Chief Operating Officer | 439490 7.1232% | $529,541.50 | 4 | 0 | |
| Gould Gregory A | Chief Financial Officer | 273565 4.4339% | $329,618.47 | 1 | 0 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$2,051,022 | 1591 | -12.84% | $76.27M | |
$22,899,264 | 81 | 34.90% | $26.7M | |
$125,860,243 | 57 | -4.48% | $54.94M | |
$2,740,482 | 50 | 9.37% | $36.33M | |
$30,209,812 | 45 | -1.91% | $8.36M |
AYTU Institutional Investors: Active Positions
| Increased Positions | 12 | +46.15% | 39,926 | +1.95% |
| Decreased Positions | 7 | -26.92% | 207,484 | -10.13% |
| New Positions | 7 | New | 36,785 | New |
| Sold Out Positions | 2 | Sold Out | 14,562 | Sold Out |
| Total Postitions | 31 | +19.23% | 2M | -8.18% |
AYTU Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Nantahala Capital Management, Llc | $1,402.00 | 18.11% | 1.09M | 0 | 0% | 2024-12-31 |
| Stonepine Capital Management, Llc | $526.00 | 6.79% | 407,549 | -93,409 | -18.65% | 2024-12-31 |
| Armistice Capital, Llc | $194.00 | 2.5% | 150,000 | -86,000 | -36.44% | 2024-12-31 |
| Renaissance Technologies Llc | $97.00 | 1.26% | 75,423 | +700 | +0.94% | 2024-12-31 |
| Geode Capital Management, Llc | $55.00 | 0.71% | 42,733 | -2,369 | -5.25% | 2024-12-31 |
| Vanguard Group Inc | $36.00 | 0.47% | 27,888 | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $29.00 | 0.38% | 22,793 | 0 | 0% | 2024-12-31 |
| Acadian Asset Management Llc | $19.00 | 0.24% | 14,622 | 0 | 0% | 2024-12-31 |
| Two Sigma Securities, Llc | $15.00 | 0.2% | 11,690 | +11,690 | New | 2024-12-31 |
| Citadel Advisors Llc | $14.00 | 0.18% | 11,062 | +11,062 | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.